At a glance
ClinicalIndex Comparison RecordPhase 3Active· 404 enrolled
Drug / intervention
IMP4927 +1 moredrug
Likely dose
IMP4927 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III Study to Evaluate the Efficacy and Safety of IMP4297 Following 1st Line Chemotherapy in the Monotherapy Maintenance Treatment of Subjects With Ovarian Cancer
In Brief
A Phase 3 clinical trial evaluating IMP4927 and Placebos for Ovarian Cancer. Active but no longer recruiting, targeting 404 participants across 2 sites.
Detailed Summary
IMP4297 is a PARP inhibitor. This is a 2:1 randomized, double-blind, placebo-controlled study conducted in patients with advanced (FIGO Stage III or IV) ovarian cancer to evaluate Efficacy and Safety of IMP4297 for Maintenance Treatment
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer
CountriesChina
Collaborators--
Timeline
Phase 3ActiveOverdue
2020202120222023202420252026
First PostedNov 2019
Enrollment StartDec 2019
Primary CompletionMar 2023
Study CompletionJun 2026
TodayJul 2026
First PostedNov 20, 2019
Enrollment StartDec 24, 2019
Primary CompletionMar 16, 2023
Study CompletionJun 30, 2026
TodayJul 1, 2026
Enrollment to primary: 3.2 yearsPosted 6.6 years ago
Interventions
IMP4927drug
IMP4297 tablet.The starting dose from 100mg QD
Placebosdrug
Placebos tablet.The starting dose from 100mg QD